{
    "clinical_study": {
        "@rank": "134423", 
        "arm_group": [
            {
                "arm_group_label": "Resveratrol", 
                "arm_group_type": "Experimental", 
                "description": "Resveratrol 500mg 3 times daily for 1 month"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 1 tablet 3 times daily for 1 month"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate potential metabolic effects of resveratrol in\n      morbidly obese women undergoing gastric bypass surgery.\n\n      The investigators hypothesize that resveratrol will:\n\n        -  Decrease hepatic very-low-density-lipoprotein-triglyceride (VLDL-TG) secretion\n\n        -  Decrease hepatic and adipose tissue VLDL-TG uptake\n\n        -  Increase insulin sensitivity\n\n      The investigators will look at changes in:\n\n        -  Lipid turnover (VLDL-TG kinetics, palmitate kinetics,calorimetry)\n\n        -  VLDL-TG uptake in different tissues (subcutaneous femoral adipose tissue, subcutaneous\n           abdominal adipose tissue, visceral adipose tissue and liver tissue)\n\n        -  Insulin sensitivity (glucose kinetics during hyperinsulinaemic euglycaemic clamp)\n\n        -  Regulation of liver fat handling\n\n        -  Lipoprotein lipase activity and fat cell size (abdominal and femoral adipose tissue)"
        }, 
        "brief_title": "Short-term Investigation of Resveratrol on Fat Metabolism in Morbidly Obese Women Undergoing Gastric Bypass Surgery", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": "Obesity"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female\n\n          -  25-60 years\n\n          -  Obesity (BMI > 35 kg/m2)\n\n          -  Have at least one element of the metabolic syndrome either hypertension and/or\n             hypercholesterolemia (high triglyceride, low HDL-cholesterol)\n\n          -  Undergoing gastric bypass surgery\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Any other relevant disease (e.g. diabetes, thyroid or parathyroid disease, heart,\n             kidney or liver disease)\n\n          -  May have arthrosis or depression\n\n          -  Any present or previous malignancy\n\n          -  History of smoking\n\n          -  Alcohol dependency (more than 14 units of alcohol per week)\n\n          -  Participation in studies with radioactive isotope within the last six months\n\n          -  Hemoglobin under the normal range regarding to sex (under 7.3 mmol/l for women)"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "25 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01826279", 
            "org_study_id": "M-20110172B"
        }, 
        "intervention": [
            {
                "arm_group_label": "Resveratrol", 
                "description": "500mg 3 times daily for 1 month", 
                "intervention_name": "Resveratrol", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Resveratrol"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "1 placebo tablet 3 times daily for 1 month", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Resveratrol"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Obesity", 
            "Gastric bypass surgery", 
            "Resveratrol", 
            "Insulin sensitivity", 
            "Lipid turnover", 
            "VLDL-triglyceride uptake", 
            "Liver"
        ], 
        "lastchanged_date": "January 29, 2014", 
        "link": {
            "description": "Official web page for the LIRMOI project, back ground info and contact", 
            "url": "http://lirmoi.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Aarhus C", 
                    "country": "Denmark", 
                    "zip": "8000"
                }, 
                "name": "Department of Endocrinology and Internal Medicine"
            }
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "Short-term Investigation of Resveratrol on Lipid Turnover in Morbidly Obese Women Undergoing Gastric Bypass Surgery. Effects on Basal and Insulin Stimulated FFA and VLDL-triglyceride Metabolism and Liver VLDL-triglyceride Uptake.", 
        "overall_official": {
            "affiliation": "Department of Endocrinology and Internal Medicine", 
            "last_name": "S\u00f8ren Nielsen, MD, associate professor, DMSc", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark: The Regional Committee on Biomedical Research Ethics", 
                "Denmark: Danish Dataprotection Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "- changes from baseline after treatment with either resveratrol or placebo", 
                "measure": "Hepatic VLDL-TG secretion and peripheral VLDL-TG clearance", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "- changes in VLDL-TG uptake in resveratrol group and placebo group", 
                "measure": "Hepatic and adipose VLDL-TG uptake", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01826279"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "- changes from baseline after treatment with either resveratrol or placebo", 
                "measure": "Basal and insulin stimulated free fatty acid (FFA) and glucose turnover", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "- changes from baseline after treatment with either resveratrol or placebo", 
                "measure": "VLDL-TG oxidation", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "- changes in regulation of liver fat handling in resveratrol group and placebo group", 
                "measure": "Regulation of liver fat handling", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }
        ], 
        "source": "University of Aarhus", 
        "sponsors": {
            "collaborator": {
                "agency": "The Ministry of Science, Technology and Innovation, Denmark", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Aarhus", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}